cas 74572-04-6|| where to buy (3R)-3-methylmorpholine

Product Name:(3R)-3-methylmorpholine

IUPAC Name:(3R)-3-methylmorpholine

Packing Unit	Available Stock	Price($)
CM104830-25g	in stock	ŹŹŉ
CM104830-100g	in stock	ǤŉǤ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 74572-04-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:74572-04-6; Molecular Formula:C5H11NO; Melting Point:-; Smiles Code:C[C@@H]1COCCN1; Density:

: Catalog Number:CM104830; Molecular Weight:101.15; Boiling Point:; MDL No:MFCD10698482; Storage:

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Lunresertib Camonsertib; Repare Therapeutics announces Fast Track Designation granted by the FDA for Lunresertib in combination with Camonsertib for the treatment of platinum-resistant ovarian cancer. Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1) is a regulator of CDK1 phosphorylation, and PKMYT1 is identified as synthetic lethal with cyclin E1 (CCNE1) amplification.
Lunresertib (RP-6306) is a first-in-class PKMYT1 inhibitor to enter clinical trial. Lunresertib is studied alone and in combination with Camonsertib in patients with advanced solid tumors. Camonsertib (RP-3500) is a potent and selective ATR inhibitor, that helps Lunresertib activate CDK1 and promotes premature mitosis. The combination is previously granted Fast Track Designation for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer.